279 related articles for article (PubMed ID: 23423980)
1. The emerging "hallmarks" of metabolic reprogramming and immune evasion: distinct or linked?
Kareva I; Hahnfeldt P
Cancer Res; 2013 May; 73(9):2737-42. PubMed ID: 23423980
[TBL] [Abstract][Full Text] [Related]
2. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
Li X; Xu W
Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
[TBL] [Abstract][Full Text] [Related]
3. A stressful microenvironment: opposing effects of the endoplasmic reticulum stress response in the suppression and enhancement of adaptive tumor immunity.
Rausch MP; Sertil AR
Int Rev Immunol; 2015 Mar; 34(2):104-22. PubMed ID: 25774773
[TBL] [Abstract][Full Text] [Related]
4. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Hurwitz AA; Watkins SK
Cancer Immunol Immunother; 2012 Feb; 61(2):289-293. PubMed ID: 22237887
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
[TBL] [Abstract][Full Text] [Related]
6. Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities.
Ganapathy-Kanniappan S
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):212-220. PubMed ID: 28400131
[TBL] [Abstract][Full Text] [Related]
7. Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity.
Wang JX; Choi SYC; Niu X; Kang N; Xue H; Killam J; Wang Y
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171818
[TBL] [Abstract][Full Text] [Related]
8. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
9. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
Jiang Z; Liu Z; Li M; Chen C; Wang X
EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888
[TBL] [Abstract][Full Text] [Related]
10. Immunometabolism: A new target for improving cancer immunotherapy.
Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
[TBL] [Abstract][Full Text] [Related]
11. GRP78 and next generation cancer hallmarks: An underexplored molecular target in cancer chemoprevention research.
Madhavan S; Nagarajan S
Biochimie; 2020 Aug; 175():69-76. PubMed ID: 32422159
[TBL] [Abstract][Full Text] [Related]
12. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
13. Major fundamental factors hindering immune system in defense against tumor cells: The link between insufficiency of innate immune responses, metabolism, and neurotransmitters with effector immune cells disability.
Bahrambeigi S; Sanajou D; Shafiei-Irannejad V
Immunol Lett; 2019 Aug; 212():81-87. PubMed ID: 31260743
[TBL] [Abstract][Full Text] [Related]
14. Innate immune mediators in cancer: between defense and resistance.
Berraondo P; Minute L; Ajona D; Corrales L; Melero I; Pio R
Immunol Rev; 2016 Nov; 274(1):290-306. PubMed ID: 27782320
[TBL] [Abstract][Full Text] [Related]
15. [Immune system and tumors].
Terme M; Tanchot C
Ann Pathol; 2017 Feb; 37(1):11-17. PubMed ID: 28159405
[TBL] [Abstract][Full Text] [Related]
16. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity.
Gujar SA; Marcato P; Pan D; Lee PW
Mol Cancer Ther; 2010 Nov; 9(11):2924-33. PubMed ID: 20978162
[TBL] [Abstract][Full Text] [Related]
17. Immunological Aspects of Cancer Cell Metabolism.
Ucche S; Hayakawa Y
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791327
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of cancer: reprogramming tumor-immune crosstalk.
Payne KK; Toor AA; Wang XY; Manjili MH
Clin Dev Immunol; 2012; 2012():760965. PubMed ID: 23097673
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunoediting: A process driven by metabolic competition as a predator-prey-shared resource type model.
Kareva I; Berezovskaya F
J Theor Biol; 2015 Sep; 380():463-72. PubMed ID: 26116366
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.
Chang CH; Qiu J; O'Sullivan D; Buck MD; Noguchi T; Curtis JD; Chen Q; Gindin M; Gubin MM; van der Windt GJ; Tonc E; Schreiber RD; Pearce EJ; Pearce EL
Cell; 2015 Sep; 162(6):1229-41. PubMed ID: 26321679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
